D3 Pharma was established in 2009 with the principal objective of developing premium-quality, clinically effective, high-dose vitamin D3 products for the prevention and treatment of vitamin D deficiency, insufficiency and associated conditions.
D3 Pharma’s licensed high-dose vitamin D3 oral products are marketed by its partners under the trade name Plenachol® 20,000 IU and 40,000 IU Capsules.
D3 Pharma continues to broaden its vitamin D3 product range to address areas of high unmet need, particularly for the paediatric and geriatric populations worldwide.